Corporate
May 13, 2014
Possible Pfizer deal draws renewed attention to merger inversions
For the time being, Pfizer Inc.'s bid to acquire London-based rival AstraZeneca PLC appears to be in limbo, and with it, the company's hopes of taking advantage of an increasingly popular merger structure.
Daily Journal Staff Writer
For the time being, Pfizer Inc.'s $106 billion bid to acquire London-based drugmaker AstraZeneca PLC appears to be in limbo, and with it, the company's hopes of taking advantage of an increasingly popular merger structure that would cut billions from its future corporate tax bills.
In addition to touting the proposed deal's strategic benefits since announcing its offer to AstraZeneca t...
For only $95 a month (the price of 2 article purchases)
Receive unlimited article access and full access to our archives,
Daily Appellate Report, award winning columns, and our
Verdicts and Settlements.
Or
$795 for an entire year!
Or access this article for $45
(Purchase provides 7-day access to this article. Printing, posting or downloading is not allowed.)
Already a subscriber?
Sign In